Insulet Corporation is primarily engaged in the development, manufacture, and sale of its proprietary continuous insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System, the Omnipod DASH Insulin Management System, the Classic Omnipod, and the Omnipod GO. The company also produces pods for Amgen for use in the Neulasta Onpro kit. Insulet sells its products directly to consumers, through distribution partners, and in the U.S. also through the pharmacy channel. The company's unique patented design allows it to provide Pod therapy at a relatively low or no up-front investment, reducing the risk to third-party payors.

• Employees: Approximately 3,000 full-time employees (as of December 31, 2023)
• Geographic Footprint: 25 countries
• Headquarters: Acton, Massachusetts
• Founded: 2000
• Number of locations/facilities: 13 facilities in 7 countries
• Revenue: $1.7 billion (FY2023)
• Key Subsidiaries/Brands: Omnipod, Omnipod 5, Omnipod DASH, Omnipod GO

• CEO: James R. Hollingshead
• Interim CFO: Lauren D. Budden

• Annual Revenue: $1.7 billion (FY2023)
• Net Income: $206.3 million (FY2023)
• Total Assets: $2.6 billion (as of December 31, 2023)
• Employees: Approximately 3,000 full-time employees (as of December 31, 2023)
• Key Financial Highlights: Revenue growth of 30% year-over-year, driven by higher volume and favorable sales channel mix.

The company's main products are continuous insulin delivery systems.

• Omnipod 5: A tubeless automated insulin delivery system that integrates with a continuous glucose monitor to manage blood sugar and is fully controlled by a compatible personal smartphone or Omnipod 5 Controller.
• Omnipod DASH: A tubeless system controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface.
• Classic Omnipod: The original tubeless insulin delivery system.
• Omnipod GO: A basal-only Pod for individuals with type 2 diabetes age 18 and older who require insulin.
• Neulasta Onpro kit: A delivery system for Amgen's Neulasta to help reduce the risk of infection after intense chemotherapy.

The company operates under one reportable segment, which is the development, manufacture, and sale of its proprietary continuous insulin delivery systems for people with insulin-dependent diabetes. Revenue is categorized by geographic location and drug delivery.

• U.S.: $1.3 billion (FY2023)
• International: $410.1 million (FY2023)
• Drug Delivery: $36.0 million (FY2023)

The company's strategic priorities include sustaining profitable growth, expanding internationally, and advancing its product pipeline. Key initiatives include:

• Launching Omnipod 5 in additional international markets.
• Expanding the indication for Omnipod 5 to include type 2 diabetes.
• Strengthening global manufacturing capabilities.
• Enhancing customer experience through digital product and data capabilities.

The diabetes medical device market is highly competitive, with major players including Medtronic and Tandem. The company also competes with companies that provide products and supplies for MDI therapy. Key market trends include technological advancements in insulin delivery and monitoring, as well as increasing awareness of insulin pump therapy. The company believes that it primarily competes with MDI therapy, which is currently the most prevalent method of insulin delivery.

• Market Risks: Competition from other insulin delivery systems and breakthrough diabetes treatments, failure to achieve wide acceptance among key stakeholders, and competitive pricing.
• Operational Risks: Manufacturing problems or capacity constraints, actual or perceived quality problems, and damage or destruction of manufacturing facilities.
• Financial Risks: Reductions in reimbursement rates or coverage policies by third-party payors, inability to secure adequate coverage, and failure to generate sufficient cash flow to service debt.
• Regulatory Risks: Adverse regulatory or legal actions relating to Omnipod products, failure to comply with FDA regulations, and failure to obtain regulatory clearances or approvals.